Cognitive Peptide · Extended Half-Life

N-Acetyl Semax: Acetylated Semax with Extended Half-Life

A UK-focused, evidence-based comparison of N-Acetyl Semax and Dihexa — mechanism, benefits, dosing, side effects, legal status, and stacking.

N-Acetyl Semax (sometimes abbreviated NA-Semax or sold as Semax NA / Semax Amidate) is a structural modification of standard Semax in which an acetyl group is added to the N-terminal methionine. This single modification dramatically increases resistance to N-terminal aminopeptidase degradation, extending the peptide’s effective CNS half-life and producing a longer per-dose duration of action than parent Semax. The acetylated variant has become the more popular form in the international nootropic community over the last decade, particularly for users who want a single morning dose to last a full workday rather than re-dosing every 4-6 hours.

What is N-Acetyl Semax?

N-Acetyl Semax is the same seven-amino-acid sequence as Semax (Met-Glu-His-Phe-Pro-Gly-Pro) with an acetyl group (CH₃CO–) attached to the N-terminal methionine, blocking aminopeptidase access. Chemically denoted Ac-Semax or N-Ac-Semax. It is not a separately registered Russian medicine — Semax (the non-acetylated form) is the approved clinical product — but the acetylated variant is widely sold by research-chemical suppliers and has been studied by the same Russian groups (Sechenov, Institute of Molecular Genetics) that developed the parent compound. Some sources also offer an "amidate" or "diamidate" variant which combines N-acetylation with C-terminal amidation for even greater protease resistance; functional differences between these forms in healthy users are not well documented.

Chemistry: N-Acetyl-Met-Glu-His-Phe-Pro-Gly-Pro · MW ~856 g/mol · Acetylated Semax
Origin: Russian variant of Semax (acetylated at N-terminus for protease resistance)
Primary route: Intranasal spray (primary)
Pharmacokinetics: CNS half-life approximately 30-50% longer than non-acetylated Semax; cognitive effects 6-8 hours per intranasal dose.
Class: Acetylated peptide · Semax derivative

Mechanism of Action

N-Acetyl Semax acts on the same molecular targets as Semax: it upregulates BDNF and NGF mRNA in hippocampus and cortex, modulates the melanocortin system (MC4R/MC5R activity without ACTH-driven cortisol release), enhances central serotonergic and dopaminergic tone, and provides cerebroprotection during ischaemic stress. The acetyl modification does not change the receptor pharmacology — it changes the pharmacokinetic profile. By blocking N-terminal degradation the peptide remains intact in CNS tissue longer, sustaining receptor exposure and producing a longer per-dose subjective duration. There is no published evidence that N-Acetyl Semax engages additional receptors or pathways beyond standard Semax; the practical difference is duration, not breadth, of effect.

Proposed Benefits

Reported benefits mirror standard Semax with an extended-duration profile. Users report a single morning intranasal dose producing 6-8 hours of clear-headed focus, sustained energy and mild emotional resilience, where standard Semax typically requires re-dosing at 3-4 hours. Cumulative benefits over 10-21 day courses include subjective improvements in working memory, learning of new material, mental stamina across demanding work, and emotional regulation under stress. The neuroprotective profile is presumed equivalent to standard Semax given identical receptor activity. Clinical use mirrors standard Semax (Russian indications: stroke, optic neuropathy, cognitive impairment, ADHD), although the acetylated form is not the registered medicinal product and is used off-label or in research settings.

Evidence Base

The dedicated published research base for N-Acetyl Semax is smaller than for standard Semax (~30-40 papers vs 200+), but the mechanism is shared so much of the parent literature is applicable. Key references include Manchenko et al. 2008 (extended-half-life pharmacokinetics in rats), Vyunova et al. 2018 (comparison of Semax and its N-acetyl variant on BDNF expression), and various Russian conference proceedings. Independent Western replication is essentially absent. There are no Phase 3 trials of N-Acetyl Semax specifically, and head-to-head comparisons against parent Semax in cognitive enhancement endpoints are not formally published.

Dosage & Administration

No medically approved dose exists for N-Acetyl Semax — it is not a registered medicine even in Russia. Community-reported nootropic protocols typically use a 300-600 µg intranasal dose once per day, taken first thing in the morning, cycled for 10-21 days followed by a 7-14 day washout. Because the half-life is longer than standard Semax, twice-daily dosing is unnecessary for most users and may increase tolerance development. Reconstitute lyophilised vials with bacteriostatic water and dispense via an intranasal applicator at the calculated concentration. Avoid sniffing hard — the goal is mucosal absorption through the cribriform plate, not pulmonary delivery.

This is a community-reported protocol summary, not a medical recommendation. There is no established human dose. Consult a qualified healthcare professional before using any research compound.

Side Effects & Risks

Side effect profile is essentially identical to standard Semax: mild nasal irritation, occasional headache in the first 1-2 days, vivid dreams, possible irritability or "wired" feeling at high doses, theoretical melanocortin-driven pigmentation effects with prolonged use. The longer half-life may slightly increase the duration of any acute side effect but does not appear to introduce new categories of risk. Contraindications remain the same: active psychotic illness, pregnancy/breastfeeding, known hypersensitivity. Long-term safety in cognitive-enhancement-style dosing in healthy adults is not formally characterised.

UK Legal Status

Same UK legal position as parent Semax. Not a controlled substance under the Misuse of Drugs Act 1971, not licensed as a medicine by the MHRA, not scheduled under the Psychoactive Substances Act 2016. Legal to purchase as a research chemical for laboratory use; cannot be sold for human consumption. WADA status: not on the 2026 Prohibited List, but athletes should confirm before competition. US status: not approved as a supplement; FDA interpretation under post-2014 dietary supplement amendments effectively prohibits commercial sale for human use.

N-Acetyl Semax vs Dihexa

N-Acetyl Semax versus Dihexa shares the broader Semax-vs-Dihexa contrast: trophic factor upregulation and melanocortin signalling versus direct HGF/c-Met activation and structural synaptogenesis. The acetylated form extends per-dose duration, making it more convenient for users seeking acute cognitive enhancement, but does not narrow the mechanistic gap with Dihexa. Dihexa’s differentiator remains structural — dendritic spine formation that persists after the molecule clears — versus Semax’s functional / transcriptional upregulation of BDNF and NGF. For users running an oral compound (Dihexa) plus a daily intranasal compound, N-Acetyl Semax is a more practical stacking partner than standard Semax because of the single-dose schedule.

Stacking with Dihexa

N-Acetyl Semax is widely stacked with Selank or N-Acetyl Selank (the classic anxiolytic-focus pair), with Dihexa for combined acute and structural support, with modafinil for high-intensity work blocks, and with Lion’s Mane mushroom extract for combined NGF / BDNF amplification. Some community protocols pair N-Acetyl Semax with low-dose lithium orotate for additional BDNF support. No published interaction data exists between N-Acetyl Semax and Dihexa specifically; the two act on distinct receptors (melanocortin vs c-Met) with no apparent mechanism for adverse interaction. Standard cautions apply: avoid with MAOIs, use stimulant combinations carefully, monitor for over-stimulation.

Frequently Asked Questions

It is not "stronger" in terms of receptor binding — the receptor pharmacology is identical. The acetyl group extends CNS half-life so each dose lasts longer (6-8 hours vs 3-4 hours), which can feel like increased potency in practice.

For convenience and a once-daily schedule, N-Acetyl Semax is the most popular. Standard Semax is the Russian clinical reference and arguably has the best-documented safety profile. The amidate / diamidate forms add C-terminal amidation for further protease resistance with limited published differential data.

Yes — they share receptor pharmacology and there is no published interaction or tolerance concern from switching. Practical reason to switch is convenience: shorter half-life forms allow more granular dosing control, longer half-life forms allow once-daily use.

Standard workplace and forensic drug tests do not screen for Semax or its variants. Sport drug testing is a separate question — see the WADA / UK Anti-Doping note in the Legal section.

At a typical 500 µg / day dose, a 30 mg vial provides approximately 60 single doses, so roughly two months of daily cycled use (allowing for washout weeks).

Once reconstituted with bacteriostatic water, refrigerate at 2-8°C and use within 14-21 days. Lyophilised (powder) vials are stable at room temperature for months but are best refrigerated for long-term storage.

The Bottom Line

N-Acetyl Semax is the more practical form of Semax for users wanting a once-daily intranasal nootropic with the same trophic-factor and melanocortin profile as the parent peptide. It does not replace Dihexa’s structural synaptogenic mechanism, but it complements it well as an acute-effect daily addition. For users new to Semax variants, the acetylated form is typically the easier starting point.